Introduction
Primary hepatic lymphoma (PHL) is a rare disease among hepatic malignancies. The incidence of PHL was reported to be less than 1% among extranodular lymphoma cases [1] . Recently, along with the introduction of methotrexate (MTX) usage for rheumatoid arthritis (RA) treatment, MTX-related malignant lymphoma cases have been increasing [2] . RA patients are susceptible to develop malignant lymphoma (ML). Moreover, these immunosuppressant drugs for RA override the occurrence of malignant diseases.
It is hypothesized that occult Epstein-Barr virus (EBV) infection relapse, which was activated by long-term usage of MTX, could cause PHL. Thus, long-term low dose usage of MTX is the risk factor for MTX-associated lymphoproliferative disorders (MTX-LPDs) [3] . Preoperative diagnosis of PHL was difficult due to the lack of characteristic radiological findings and its low incidence among liver malignancies. On computed tomography (CTs), low-density mass lesions are revealed, while on contrasted CT, tumors showed ischemic patterns. Further, T1-and T2-weighted magnetic resonance images (MRI) revealed low intense and high intense areas, respectively. However, these findings were not specific [4, 5] . Portal or hepatic veins extended through a hepatic lesion without evidence of appreciable mass effect, occlusion, or displacement of the vessels. These findings were also not specific, but can be used as a basis for suspicion [6] . Although increasing numbers of MTX-ML cases have been reported, the condition remains rare. This is the first case of solitary PHL without distant metastasis that developed during MTX treatment for RA. Our case demonstrated an MTX-associated PHL following curative resection supported with review of literatures.
Presentation of case
A 65-year-old woman was admitted for the treatment of her liver tumor in April 2015. Her height and weight were 146 cm and 48 kg, respectively. She is a hepatitis B virus carrier and has a history of RA. MTX was introduced seven years prior for RA treatment. Her laboratory data showed no elevation of several tumor markers. Both her physical examination and liver function test results were normal. On abdominal echo, a low echoic tumor was detected at segment 6 (S6), with a size of 16 × 29 mm. On contrasted CT, the tumor was slightly enhanced at the early phase, and tumor staining was sustained at the delayed phase (Fig. 1a-d) . MRI showed that the tumor was weakly enhanced at the early phase, and revealed hypo intense areas at both late and hepatobiliary phases ( Fig. 2a-d) . The differential diagnoses include well-differentiated hepatocellular carcinoma, intrahepatic cholangiocarcinoma, metastatic liver tumor, and PHL. Subsegmentectomy of the S6 was performed with an operative time of 252 min and intraoperative bleeding amount of 240 mL. The specimen shows that the tumor was a whitish solid with an irregular margin (Fig. 3) . The final pathological diagnosis was MTX-associated PHL. On immunohistochemical analysis, CD20, CD30, and CD79a were positive, but CD10 and CD15 were negative (Fig. 4) . EBER (EBV-encoded small RNA) was also positive. These findings were consistent with non-Hodgkin's lymphoma (NHL), diffuse large B cell lymphoma (DLBCL), and other iatrogenic immunodeficiency-associated lymphoproliferative disorders (LPDs) according to the WHO 2008 classification of lymphoid tissue. However, positron emission tomography (PET)-CT and bone marrow aspiration sample did not indicate any sign of ML.
The patient was discharged in our department without any complication, and was transferred to the hematology department of Kawasaki University. Additionally, bone marrow aspiration was performed, but residual tumor cells were not detected. She survived with no recurrence for one year even without any additional chemotherapy. MTX withdrawal was effective for the recurrence of ML afterwards.
Discussion
MTX-associated PHL following curative hepatectomy was demonstrated. To date, only a few reports of MTX associated with PHL were seen [1, 2, 7] (Table 1) . In all cases, the pathological diagnosis was DLBCL. Diagnosis was performed with biopsy in all three cases, and the treatment was chemotherapy: either R-CHOP (rituximab, cyclophosphamide, hydroxyldaunorubicin, oncovin, prednisone) or R-THP-COP (rituximab, 4 -O-tetrahydropyranyl adriamycin, cyclophosphamide, oncovin, prednisone). In the present case, surgery was performed as both a therapeutic and diagnostic procedure, and follow-up was done after MTX discontinuation without chemotherapy.
In 1991, the association between lymphoma and MTX therapy in patients with RA was first reported by Ellman et al. [8] . Patients with RA have various immunologic abnormalities, including Tcell dysfunction and B-cell activation associated with autoantigen stimulation [9] . The high inflammatory activity in these patients associated with RA, immunosuppressive agents including MTX used for treatment, or EBV infection/reactivation. In Japan, 95% of adults with latent infection of B-cells throughout their life were infected with EBV. In addition to EBV infection, immunologic abnormality and gene alteration in the infection cells encour- age carcinogenic occurrences. In our case, EBV was positive and relapsed due to MTX usage, which was considered as a reason for the occurrence of PHL.
RA patients have a modestly increased risk of developing LPDs independent of immunosuppressive therapy for the disease. In RA treatment, the most popular immunosuppressive agent is MTX. MTX is usually used for several malignant diseases such as lymphoblastoma, trophoblastic disease, and leukemia. In one study on 29 RA patients with MTX-LPD, the median durations of RA and MTX treatment were reported to be 96 and 56 months, respectively, with a median cumulative dose of 864 mg [10] . In the present case, the duration of MTX treatment was 84 months, and the total dose of MTX was over 25,550 mg. This suggests that the immunosuppressive state induced by MTX may have played a major role in the development of PHL in the current patient.
Previous reports have indicated that EBV may be related to the development of MTX-LPD [11, 12] . Forty-six percent of MTX-LPD patients exhibited EBV-positive findings in the nuclei of the atypical cells of lymphoma [13] . Cell cycle dysregulation and latent EBV infection have been reported to be important factors for the development of LPD in autoimmune disease patients with an immunosuppressed condition due to treatment with MTX [14] . Further, EBV may be associated with spontaneous regression following the withdrawal of MTX in MTX-LPD patients. Salloum et al. reported that EBV was detected in eight out of ten patients who responded to the withdrawal of MTX, whereas only one of six EBV-negative patients responded to MTX withdrawal [15] . Therefore, the presence of EBV may be a predictive factor for the efficacy of MTX withdrawal.
Treatment option of PHL include surgery, chemotherapy, radiation, or carrying out combinations of these modalities [16] . However, the optimal treatment is not established due to the heterogeneous occurrence patterns in patients. Chemotherapy with CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone)-based regimens is generally the gold standard [16, 17] . The role of surgery is not fully clarified, but there are reports that liver resection followed by adjuvant chemotherapy and/or radiation results in better prognosis [16, 18] . However, approximately 55% of MTX-LPD patients have been reported to improve following the withdrawal of MTX, without additional antitumor therapy [15] . Diagnosis has been difficult using the preoperative imaging tests, but malignant tumor was suspected from the size observed. We considered that curative resection was possible for a solitary lesion. Therefore, we performed surgery for its diagnosis and treatment. The pathological diagnosis was ML. Generally, it is better to take adjuvant chemotherapy. However, in the MTX-related ML, withdrawing MTX could be an effective therapy. In our case, we suspected MTX-related ML since the medical history of the patient reveals she was taking MTX. After the diagnosis of ML with surgery, we opted to withdraw MTX without adjuvant chemotherapy for the reason mentioned above.
Precise diagnosis played an important role in selecting the appropriate treatment. Therefore, it is important to consider MTXrelated ML in patients with a history of MTX usage.
Conclusion
The frequency of MTX-associated PHL is rare, and the lack of characteristic findings makes it difficult to make a precise diagnosis.
Long-term MTX use encouraged MTX-related ML, and withdrawing MTX alone could have a therapeutic effect. Therefore, it is important to monitor for PHL occurrence in patients treated with MTX on a long-term basis.
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